During shortages of Wegovy, Ozempic, Mounjaro, and Zepbound, the FDA exercised temporary enforcement discretion , allowing compounding pharmacies to help meet patient demand. Once manufacturing stabilized: Semaglutide injection products were removed from the FDA Drug Shortage List Tirzepatide injection products were formally declared resolved Compounding reverted to pre-shortage federal and state limits Broad, shortage-based compounding is no longer allowed in 2026
What is the FDAs decision to ban compounded medications about
These include nausea, vomiting, diarrhea, constipation, and abdominal pain
This is psychologically easier for some people during the transition, even though mathematically any concentration works fine as long as you calculate correctly
Food and Drug Administration (FDA) for chronic weight management in adults with a starting, or baseline, body mass index (BMI) of 30 or more (obesity)